MSCRF Commercialization Program supports companies developing human stem cell technologies, funding feasibility and advanced development work to move promising products toward clinical development or market entry.
Funder: Maryland Technology Development Corporation (TEDCO)
Due Dates: January 20, 2027, at 5:00 p.m. EST (Application) | Week of April 4, 2027 (In-person review) | May 2027 (Award announcement)
Funding Amounts: Level 1: up to $250,000; Level 2: up to $400,000; eligible collaborations add up to $100,000; 12 months
Summary: Supports companies advancing commercially promising human stem cell technologies toward clinical development or market entry.
Key Information: All project research must occur in Maryland; shortlisted applicants’ PI and CEO must present in person.
The Maryland Stem Cell Research Fund (MSCRF), an independent program within TEDCO, supports translational activities that move human stem cell technologies with significant commercial potential toward clinical development or market entry. Eligible technologies include therapeutics, diagnostics, research tools, devices, enabling or supportive technologies, and products involving stem cell derivatives such as extracellular vesicles and secretome.
The Commercialization Program offers two development levels: early-stage feasibility and risk reduction, and advanced development built on validated proof-of-concept. Its goals include advancing strategies for preventing, diagnosing, treating, and curing human diseases, injuries, and conditions. Supplementary funding encourages collaboration between companies and Maryland research institutions on research integral to technology development.